Deglycosylation of SEMA7A augmented the sensitivity of HNSCC to EGFR-targeted therapy and attenuated immunosuppression, thus facilitating the response to anti-PD-L1-based immunotherapy (Fig. 10). This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.